NO20091158L - Hoyselektive reopptaksinhibitorer for norepinefrin - Google Patents

Hoyselektive reopptaksinhibitorer for norepinefrin

Info

Publication number
NO20091158L
NO20091158L NO20091158A NO20091158A NO20091158L NO 20091158 L NO20091158 L NO 20091158L NO 20091158 A NO20091158 A NO 20091158A NO 20091158 A NO20091158 A NO 20091158A NO 20091158 L NO20091158 L NO 20091158L
Authority
NO
Norway
Prior art keywords
reboxetine
norepinephrine
reuptake inhibitors
high selective
selective reuptake
Prior art date
Application number
NO20091158A
Other languages
English (en)
Inventor
Erik Ho Fong Wong
Robert Clyde Marshall
Saeeduddin Ahmed
Robert Mcarthur
Duncan P Taylor
Lars Birgerson
Pasquale Cetera
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091158(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20091158L publication Critical patent/NO20091158L/no
Application filed by Upjohn Co filed Critical Upjohn Co

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anvendelse av optisk rent (S,S)-reboxetin, eller et farmasøytisk akseptabelt salt derav, til fremstilling av et medikament for behandling eller forebyggelse av kronisk utmattelsessyndrom, hvor det optiske rene (S,S)-reboxetin eller et farmasøytisk akseptabelt salt derav omfatter minst 90 vekt% (S,S)reboxetin og mindre enn 10 vekt% (R,R)-reboxetin, basert på totalvekten av (S,S)- og (R,R)-reboxetin som er til stede.
NO20091158A 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin NO20091158L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13
PCT/US2000/017256 WO2001001973A2 (en) 1999-07-01 2000-06-22 Highly selective norepinephrine reuptake inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
NO20091158L true NO20091158L (no) 2002-02-19

Family

ID=27495506

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20016406A NO20016406L (no) 1999-07-01 2001-12-28 Höyselektive reopptaksinhibitorer for norepinefrin
NO20091158A NO20091158L (no) 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091159A NO20091159L (no) 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091168A NO20091168L (no) 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20016406A NO20016406L (no) 1999-07-01 2001-12-28 Höyselektive reopptaksinhibitorer for norepinefrin

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20091159A NO20091159L (no) 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091168A NO20091168L (no) 1999-07-01 2009-03-18 Hoyselektive reopptaksinhibitorer for norepinefrin

Country Status (31)

Country Link
US (18) US6465458B1 (no)
EP (3) EP2090312A1 (no)
JP (3) JP2003503450A (no)
KR (5) KR100704319B1 (no)
CN (5) CN1660110A (no)
AR (1) AR035158A1 (no)
AT (9) ATE292971T1 (no)
AU (2) AU771258B2 (no)
BR (1) BR0012136A (no)
CA (2) CA2643231A1 (no)
CL (3) CL2008002868A1 (no)
CO (1) CO5190662A1 (no)
CZ (1) CZ299847B6 (no)
DE (9) DE60026627T2 (no)
DK (4) DK1459750T3 (no)
EA (6) EA200801805A1 (no)
ES (9) ES2246487T3 (no)
GE (1) GEP20094798B (no)
HK (2) HK1049630A1 (no)
HU (1) HUP0201623A3 (no)
IL (3) IL147246A0 (no)
MX (1) MXPA02000562A (no)
MY (1) MY137348A (no)
NO (4) NO20016406L (no)
NZ (2) NZ533243A (no)
PE (1) PE20010684A1 (no)
PL (1) PL196996B1 (no)
PT (5) PT1632234E (no)
SK (5) SK286668B6 (no)
TW (9) TW200407146A (no)
WO (1) WO2001001973A2 (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
ATE361751T1 (de) * 1999-12-01 2007-06-15 Ucb Sa Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
CN1554343A (zh) 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ 用于治疗纤维肌痛和慢性疲劳综合症的化合物
JP2004502651A (ja) * 2000-04-21 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 線維筋痛症および慢性疲労症候群の治療
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
CA2426069A1 (en) * 2000-11-15 2002-05-23 David Michelson Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
ATE452642T1 (de) * 2001-06-19 2010-01-15 Norbert Mueller Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NZ532065A (en) * 2001-12-11 2007-03-30 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
BR0311878A (pt) * 2002-06-17 2005-04-05 Pharmacia Italia Spa Sais farmacêuticos de reboxetina
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
AU2003261245A1 (en) * 2002-08-23 2004-03-11 Eli Lilly And Company Benzyl morpholine derivatives
CA2500662A1 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
DE602004019698D1 (de) * 2003-12-23 2009-04-09 Lilly Co Eli Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
PL1789021T3 (pl) 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
WO2006038084A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2363123A1 (en) * 2006-06-28 2011-09-07 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2008112562A1 (en) 2007-03-09 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008134325A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
TWI438190B (zh) * 2008-07-24 2014-05-21 Theravance Inc ３－（苯氧基苯基甲基）吡咯啶化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN102471258A (zh) * 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
IL293536A (en) * 2019-12-03 2022-08-01 Axsome Therapeutics Inc Use of reboxetine to treat disease states in the nervous system

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
DK0856312T3 (da) 1996-11-27 1999-06-23 Pfleger R Chem Fab Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
JP2002503224A (ja) 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
WO1999052531A1 (en) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
HUP0101341A3 (en) * 1998-05-08 2006-07-28 Upjohn Co New drug combinations
KR20010078754A (ko) 1998-06-29 2001-08-21 추후제출 통증 경감 방법 및 통증 경감용 경피 조성물
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
ES2246487T3 (es) 2006-02-16
DE60022916D1 (de) 2006-02-09
ES2246488T3 (es) 2006-02-16
ATE305307T1 (de) 2005-10-15
CA2375908C (en) 2006-05-30
US6703389B2 (en) 2004-03-09
CA2643231A1 (en) 2001-01-11
US20040147614A1 (en) 2004-07-29
TWI293250B (en) 2008-02-11
US20060142289A1 (en) 2006-06-29
DE60020613T2 (de) 2006-03-16
SK286667B6 (sk) 2009-03-05
AR035158A1 (es) 2004-05-05
ES2258010T3 (es) 2006-08-16
US20060128705A1 (en) 2006-06-15
KR20090087135A (ko) 2009-08-14
DE60022692T2 (de) 2006-06-22
ES2258251T3 (es) 2006-08-16
DK1632234T3 (da) 2007-09-17
PL196996B1 (pl) 2008-02-29
CZ20014625A3 (cs) 2002-08-14
US7338953B2 (en) 2008-03-04
WO2001001973A8 (en) 2001-05-17
CO5190662A1 (es) 2002-08-29
ES2239311T3 (es) 2005-09-16
DE60022692D1 (de) 2005-10-20
SK286669B6 (sk) 2009-03-05
SK19382001A3 (sk) 2002-07-02
JP2006321815A (ja) 2006-11-30
EA200801805A1 (ru) 2008-12-30
DE60019473T2 (de) 2006-02-23
US20060135521A1 (en) 2006-06-22
SK286104B6 (sk) 2008-03-05
TW200920378A (en) 2009-05-16
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
CN1289090C (zh) 2006-12-13
EP2087892A2 (en) 2009-08-12
MXPA02000562A (es) 2002-07-02
DE60035232D1 (de) 2007-07-26
NO20091159L (no) 2002-02-19
DE60022917D1 (de) 2006-02-09
HK1076723A1 (en) 2006-01-27
US7276503B2 (en) 2007-10-02
DE60022916T2 (de) 2006-07-06
DE60026704D1 (de) 2006-05-11
IL187513A0 (en) 2008-06-05
PE20010684A1 (es) 2001-06-24
EA200700232A1 (ru) 2007-06-29
TW200407146A (en) 2004-05-16
TWI298254B (en) 2008-07-01
DE60022917T2 (de) 2006-06-29
HUP0201623A2 (en) 2002-09-28
HK1049630A1 (en) 2003-05-23
US20060135520A1 (en) 2006-06-22
CL2008002866A1 (es) 2009-01-09
PT1459750E (pt) 2005-08-31
AU771258B2 (en) 2004-03-18
ATE320257T1 (de) 2006-04-15
DK1459749T3 (da) 2006-01-09
DE60023043T2 (de) 2006-06-14
TWI298255B (en) 2008-07-01
MY137348A (en) 2009-01-30
ATE364386T1 (de) 2007-07-15
EP2087892A3 (en) 2009-09-30
ATE304358T1 (de) 2005-09-15
KR100704319B1 (ko) 2007-04-09
US7723334B2 (en) 2010-05-25
BR0012136A (pt) 2002-06-11
CN1660110A (zh) 2005-08-31
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
NO20091168L (no) 2002-02-19
US20080103147A1 (en) 2008-05-01
NZ533243A (en) 2005-12-23
US6610690B2 (en) 2003-08-26
DE60023043D1 (de) 2006-02-16
PT1459751E (pt) 2005-11-30
EP1196172A2 (en) 2002-04-17
EA005029B1 (ru) 2004-10-28
SK286668B6 (sk) 2009-03-05
ATE296634T1 (de) 2005-06-15
DK1459750T3 (da) 2005-08-15
CL2008002867A1 (es) 2009-01-09
US20080103145A1 (en) 2008-05-01
KR100717660B1 (ko) 2007-05-15
KR20020015363A (ko) 2002-02-27
ATE319453T1 (de) 2006-03-15
JP2006143749A (ja) 2006-06-08
EA200400589A1 (ru) 2004-12-30
HUP0201623A3 (en) 2004-12-28
NZ515885A (en) 2004-08-27
EA006652B1 (ru) 2006-02-24
PT1196172E (pt) 2006-05-31
CN1379672A (zh) 2002-11-13
CN1205935C (zh) 2005-06-15
ATE305788T1 (de) 2005-10-15
JP2003503450A (ja) 2003-01-28
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
TWI245631B (en) 2005-12-21
EP1196172B1 (en) 2006-03-15
ES2242175T3 (es) 2005-11-01
US6642235B2 (en) 2003-11-04
TW200607510A (en) 2006-03-01
CN1660111A (zh) 2005-08-31
US20080096890A1 (en) 2008-04-24
TWI294779B (en) 2008-03-21
US6987107B2 (en) 2006-01-17
IL147246A0 (en) 2002-08-14
SK286864B6 (sk) 2009-06-05
US6465458B1 (en) 2002-10-15
PL352252A1 (en) 2003-08-11
GEP20094798B (en) 2009-10-26
DE60035232T2 (de) 2008-02-14
EA011094B1 (ru) 2008-12-30
CZ299847B6 (cs) 2008-12-10
US20060264436A1 (en) 2006-11-23
DE60019473D1 (de) 2005-05-19
ES2285645T3 (es) 2007-11-16
US20020061910A1 (en) 2002-05-23
CN1660109A (zh) 2005-08-31
US20020128173A1 (en) 2002-09-12
CL2008002868A1 (es) 2009-01-09
KR100948757B1 (ko) 2010-03-23
KR20060099544A (ko) 2006-09-19
KR20050053799A (ko) 2005-06-08
EP2090312A1 (en) 2009-08-19
ES2246485T3 (es) 2006-02-16
WO2001001973A3 (en) 2002-01-17
CN1660108A (zh) 2005-08-31
EA008381B1 (ru) 2007-04-27
KR100935277B1 (ko) 2010-01-06
US20080103146A1 (en) 2008-05-01
US20030040464A1 (en) 2003-02-27
TW200607509A (en) 2006-03-01
US20020107249A1 (en) 2002-08-08
NO20016406L (no) 2002-02-19
TW200914027A (en) 2009-04-01
WO2001001973A2 (en) 2001-01-11
TW200607511A (en) 2006-03-01
EA200801806A1 (ru) 2008-12-30
NO20016406D0 (no) 2001-12-28
EA200200111A1 (ru) 2002-06-27
DE60020613D1 (de) 2005-07-07
IL187512A0 (en) 2008-06-05
ES2247572T3 (es) 2006-03-01
PT1632234E (pt) 2007-07-09
DE60026704T2 (de) 2006-10-19
US7317011B2 (en) 2008-01-08
ATE305306T1 (de) 2005-10-15
ATE292971T1 (de) 2005-04-15
US20090247528A1 (en) 2009-10-01
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
AU2004202096B2 (en) 2005-10-20
AU5633700A (en) 2001-01-22
AU2004202096A1 (en) 2004-06-10
KR20090087134A (ko) 2009-08-14
TW200607512A (en) 2006-03-01
EA200501496A1 (ru) 2006-06-30
US7241762B2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
NO20091158L (no) Hoyselektive reopptaksinhibitorer for norepinefrin
DK0736004T3 (da) (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler
WO1999040904A3 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
MX9706785A (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
DK1796484T3 (da) Konfektureprodukt
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
NO20012977L (no) N-ureidoalkylpiperidiner som modulatorer av chemokinreseptoraktivitet
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
NO960653L (no) Nytt, farmasöytisk middel for oral administrering omfattende progesteron og en polyetylenglykol sammen med en eksipiens
NZ530037A (en) Use of glycosaminoglycans for the treatment of HIV-associated nephropathy
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
AU2002357972A1 (en) Heparin-containing ophthalmic agent
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
NO20062857L (no) Farmasoytisk preparat omfattende et sink-hyaluronatkompleks for behandling av multippel sklerose
WO2005091987A3 (en) Method of treating down syndrome
NO996049D0 (no) Kontrollert-frigjøring farmasoeytisk preparat med ACE inhibitor som aktivt middel
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
NO985571L (no) Legemiddel for autoimmunsykdommer
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
NO984974L (no) Middel som forbedrer pulmonar sirkulasjon
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure